Crossmark

Letter in reply to: Enhancing the understanding of anti-VEGF treatment failure in retinal vascular diseases: a call for expanded analyses and threshold validation

Crossref DOI link: https://doi.org/10.1038/s41433-025-03681-w

Published Online: 2025-02-19

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fu, Dun Jack https://orcid.org/0000-0003-2852-6912
Sivaprasad, Sobha https://orcid.org/0000-0001-8952-0659
Faes, Livia
License Information

Text and Data Mining valid from 2025-02-19

Version of Record valid from 2025-02-19
More Information

Article History

Received: 13 January 2025

Revised: 19 January 2025

Accepted: 3 February 2025

First Online: 19 February 2025

Competing interests

: Allergan (an AbbVie company, Irvine, CA, USA). The sponsor or funding organisation participated in the review and approval of the manuscript as report 1 of the investigator-initiated trial grant SIMD1004 (this manuscript represents report 1 of at least 2 to come from SIMD1004). No honoraria or payments were made for authorship. DJF: Funding/fees outside the submitted work with Allergan, Apellis, Google Health and DeepMind. Member of the Eye editorial board. SS: Funding/fees from AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, Eyepoint Pharmaceuticals, Janssen Pharmaceuticals, Novo Nordisk, Optos, Ocular Therapeutix, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics. Sanofi. Member of the Eye editorial board. LF: Other relevant financial activities outside the submitted work with Bayer and Allergan. Member of the Eye editorial board.

Document is current

Any future updates will be listed below